ArticlePloS one2026
Associating Mycobacterium tuberculosis genomic variants with minimum inhibitory concentrations to delamanid and pretomanid.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Emerging resistance to delamanid (DLM) and pretomanid (Pa) threatens drug-resistant tuberculosis (DR-TB) treatment outcomes. The lack of rapid molecular diagnostics, due to limited knowledge of resistance-conferring mutations, along with standardization challenges for critical concentrations (CC) in phenotypic drug susceptibility testing (pDST) hinder resistance detection. Here, we explore the correlation between minimum inhibitory concentrations (MICs) and genomic variants of DLM and Pa resistance in Mycobacterium tuberculosis (Mtb). Seventeen Mtb isolates phenotypically resistant to DLM detected through routine pDST using the Mycobacterial Growth Indicator Tube (MGIT) system from 2021-2024 were selected from the National Reference Laboratory biobank in Tbilisi, Georgia. DLM/Pa MICs were determined using the Resazurin Microtiter Assay (REMA) with a DLM concentration range of 0.008-2 µg/ml, and a broader range of 0.125-32 µg/ml was utilized for Pa. To identify mutations associated with DLM/Pa resistance, isolates were subjected to whole genome sequencing (WGS). Of the seventeen Mtb isolates phenotypically resistant to DLM, eight (47%) manifested a MIC value below the DLM CC (0.06 µg/ml), with only one carrying a mutation in a gene associated with DLM/Pa resistance (fbiC). Among the remaining nine isolates with MICs above the CC, the premature stop codon mutation W88* in ddn gene predominated, present in five cases and associated with elevated DLM and Pa MICs (0.125-2 µg/ml and 2-8 µg/ml, respectively). Three isolates (19%) harbored novel, previously undescribed genetic variants, all within genes previously linked to resistance DLM/Pa (G35fs in ddn, Q317R and Q279H in fgd1, and C565W in fbiC). Our results support DLM and Pa resistance association with W88* and W678G mutations in ddn and fbiC genes respectively, currently graded as "uncertain significance" in the WHO catalogue of Mtb drug resistance-conferring mutations. Additionally, we observed previously undescribed mutations exclusively within genes linked to DLM/Pa susceptibility, prompting further investigation of their role in resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.